drugset / Trial / NCT03815344

Combined Vaginal Misoprostol and Perivascular Vasopressin

NCT03815344

Phase 4 Completed 74 enrolled Antonios Likourezos
RandomizedParallel-groupQuadruple-blindPrevention

Summary

Injection of Vasopressin into the uterine tissue surrounding fibroids constricts blood vessels, and has been found to be beneficial by decreasing blood flow to fibroids, and thereby resulting in less bleeding with removal. Additionally, Misoprostol has been looked at as an additional method to decrease operative blood loss given its ability to increase uterine muscle tone, which therefore constricts the amount of blood flow to the uterus.

Timeline

Start
2017-04-26
Primary completion
2019-06-30
Completion
2019-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Misoprostol Other / unclassified 400 ug Other
Subject Vasopressin Peptide 20 iu Other

Indications